Skip to main content

Table 1 IC50 values for EGFR-targeted TKIs in control and AnxA6-depleted invasive breast cancer cells

From: Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors

EGFR-targeted TKI

BT-549-EV

BT-549-A6sh

Fold change EV:A6sh

P-value EV:A6sh

PD153035

6.46 ± 0.62

4.16 ± 0.12

1.55

0.02*

Lapatinib

14.09 ± 1.75

5.99 ± 1.77

2.35

0.03*

Canertinib

4.30 ± 0.24

3.96 ± 0.11

1.09

0.10

Gefitinib

14.43 ± 0.71

13.51 ± 2.83

1.07

0.80

  1. IC50 - half maximal inhibitory concentration (μM) estimated from the regression plots for the indicated tyrosine kinase inhibitors (TKI). BT-549-EV, control BT-549 cells; BT-549-A6sh, AnxA6-depleted BT-549 cells. For fold change and p-values, EV: A6sh denotes, BT-549 control cells versus AnxA6-depleted cells. *Statistically significant at p < 0.05.